Drug Trial Radar · NCT00912925
Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I
Last checked: Nov 20, 2026Latest source record: Apr 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Dec 2000
Primary completion
Sep 2001
Study completion Sep 2001
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- BioMarin/Genzyme LLC
- First posted
- Jun 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients
Conditions
- Mucopolysaccharidosis I
- Hurlers Syndrome
- Hurler-Scheie Syndrome
Interventions
rhIDU (recombinant human-Alpha-L-Iduronidase)Biological
Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
PlaceboBiological
Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC)Time frame: Baseline to Week 26
- Overall Change From Baseline to Week 26 in Six Minute Walk Test (6MWT)Time frame: Baseline to Week 26
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Vancouver, British Columbia, Canada
Site not named
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.